@article{JTD8193,
author = {György Losonczy},
title = {Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {7},
year = {2016},
keywords = {},
abstract = {Crizotinib is the first approved ALK inhibitor in advanced, ALK-positive non-small cell lung cancer (NSCLC). When administered in first line, median progression-free survival (mPFS) was 10.9 months (ms) with crizotinib versus 7.0 ms with best cytostatic chemotherapy. Overall response rate was 74% with crizotinib versus 45% with chemotherapy (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/8193}
}